Lisata Therapeutics (NASDAQ:LSTA) Issues Quarterly Earnings Results

Lisata Therapeutics (NASDAQ:LSTA) issued its quarterly earnings data on Monday. The company reported ($0.50) EPS for the quarter, FiscalAI reports.

Lisata Therapeutics Stock Up 3.6%

NASDAQ LSTA traded up $0.11 on Monday, hitting $3.26. The company’s stock had a trading volume of 58,687 shares, compared to its average volume of 144,820. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $5.07. The company’s 50-day moving average is $4.37 and its 200 day moving average is $3.33. The firm has a market cap of $29.74 million, a PE ratio of -1.71 and a beta of 0.81.

Analyst Ratings Changes

LSTA has been the subject of several research reports. downgraded shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $15.00.

Hedge Funds Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cerity Partners LLC acquired a new stake in shares of Lisata Therapeutics during the second quarter worth $32,000. Ground Swell Capital LLC bought a new stake in Lisata Therapeutics during the third quarter valued at $62,000. Renaissance Technologies LLC grew its holdings in Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the 3rd quarter worth about $37,000. Finally, SOL Capital Management CO bought a new position in shares of Lisata Therapeutics in the 1st quarter worth about $61,000. 8.94% of the stock is currently owned by institutional investors and hedge funds.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.